Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Nuvalent Inc (NUVL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: NUVL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $117.3
1 Year Target Price $117.3
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.91% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.78B USD | Price to earnings Ratio - | 1Y Target Price 117.3 |
Price to earnings Ratio - | 1Y Target Price 117.3 | ||
Volume (30-day avg) 11 | Beta 1.34 | 52 Weeks Range 55.53 - 113.51 | Updated Date 07/4/2025 |
52 Weeks Range 55.53 - 113.51 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.23% | Return on Equity (TTM) -35.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4705944406 | Price to Sales(TTM) - |
Enterprise Value 4705944406 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -22.26 | Shares Outstanding 66373500 | Shares Floating 41264189 |
Shares Outstanding 66373500 | Shares Floating 41264189 | ||
Percent Insiders 2.85 | Percent Institutions 110.02 |
Upturn AI SWOT
Nuvalent Inc
Company Overview
History and Background
Nuvalent, Inc. is a biotechnology company focused on developing precisely targeted therapies for patients with cancer. Founded in 2017, the company's mission is to address the unmet medical needs of patients with kinase-driven cancers by designing innovative small molecule kinase inhibitors.
Core Business Areas
- Precision Oncology: Nuvalent focuses on developing selective kinase inhibitors to target specific oncogenic drivers, minimizing off-target effects and improving patient outcomes.
- Drug Discovery and Development: The company is involved in all stages of drug development, from initial discovery to clinical trials and potential commercialization.
Leadership and Structure
Nuvalent is led by a management team with experience in oncology drug development and commercialization. The company has a board of directors providing strategic oversight.
Top Products and Market Share
Key Offerings
- NVL-520: An investigational ROS1-selective tyrosine kinase inhibitor (TKI) designed to address limitations of existing ROS1 inhibitors. Currently in clinical development. Competitors include Pfizer (XALKORI), Roche (ROZLYTREK), and Bristol Myers Squibb (AUGTYRO). No market share/revenue yet as it is in clinical trials.
- NVL-655: An ALK-selective tyrosine kinase inhibitor (TKI) for patients with ALK-positive NSCLC resistant to current therapies. Currently in clinical development. Competitors include Roche (ALECENSA), Novartis (Zykadia) and Takeda (Alunbrig). No market share/revenue yet as it is in clinical trials.
Market Dynamics
Industry Overview
The oncology market is a large and growing market, driven by increasing cancer incidence, advances in diagnostics and treatments, and an aging population. Precision oncology, which targets specific genetic mutations driving cancer growth, is a rapidly expanding segment.
Positioning
Nuvalent is positioned as a precision oncology company focused on developing highly selective kinase inhibitors to address unmet needs in specific cancer subtypes. Its competitive advantage lies in its focus on selectivity, addressing resistance mechanisms, and its pipeline of novel drug candidates.
Total Addressable Market (TAM)
The TAM for targeted cancer therapies is estimated to be in the tens of billions of dollars globally. Nuvalent is positioned to capture a portion of this market with its pipeline of selective kinase inhibitors, targeting specific cancer subtypes with high unmet need.
Upturn SWOT Analysis
Strengths
- Highly selective kinase inhibitors
- Focus on addressing resistance mechanisms
- Strong management team with oncology expertise
- Innovative drug discovery platform
- Promising clinical trial results
Weaknesses
- Early-stage clinical development
- Dependence on clinical trial success
- High R&D expenses
- Limited commercialization experience
- Reliance on patents for protection
Opportunities
- Potential to address unmet needs in specific cancer subtypes
- Expansion of pipeline with new drug candidates
- Partnerships with larger pharmaceutical companies
- Acquisition by a larger pharmaceutical company
- Positive clinical trial data leading to regulatory approvals
Threats
- Clinical trial failures
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- PFE
- ROG.SW
- BMY
- TAK
Competitive Landscape
Nuvalent has a competitive advantage in the selectivity of its kinase inhibitors. Its disadvantages include being in early-stage clinical development compared to competitors with approved products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancing drug candidates through preclinical and clinical development.
Future Projections: Future growth is dependent on successful clinical trials and potential regulatory approvals. Analyst estimates vary but generally reflect optimism based on the potential of Nuvalent's pipeline.
Recent Initiatives: Recent initiatives include advancing NVL-520 and NVL-655 through clinical trials, expanding the pipeline with new drug candidates, and presenting data at scientific conferences.
Summary
Nuvalent is a promising clinical-stage biotechnology company focused on precision oncology with a strong pipeline of selective kinase inhibitors. Its success hinges on positive clinical trial results and regulatory approvals. Key strengths include innovative drug discovery and a focus on unmet needs. The company needs to navigate clinical trial risks and competitive pressures effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Nuvalent Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated and may vary. Clinical trial outcomes are inherently uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvalent Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-07-29 | CEO, President & Director Dr. James R. Porter Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 162 | Website https://www.nuvalent.com |
Full time employees 162 | Website https://www.nuvalent.com | ||
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.